ALLR
NASDAQAllarity Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks39+25%
2026-04-192026-10-11
Mix1290d
- SEC Filings6(50%)
- Other4(33%)
- Offering1(8%)
- Insider1(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Allarity Therapeutics Inc.4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib’s clinical development while expanding external partnership opportunities. Allarity Therapeutics
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research. The new capabilities build on the laboratory’s existing transcriptomics rese
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib DevelopmentTARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, provides protection in Japan into 2039. Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: "Japan is one of the world’s largest pharmaceutical markets and is also the home
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementTARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its units. The proposed initial public offering is expected to have a base offering size of $100 million, or $115
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- SECSEC Form 10-Q filed by Allarity Therapeutics Inc.10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®-guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S. clinical trials TARPON SPRINGS, Fla., AUGUST 14, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to de
- PRAllarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA RegistrationAllarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environmentCLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity’s lead agent, stenoparibPositions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion DiagnosticKey U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent has a term extending into April 2042. The patent grant follows the USPTO’s Notice of Allowanc
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that it will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17–19 in Copenhagen, Denmark. The poster outlines the scientific background, study design, and clinical rationale for the Company's ongoing Phase 2 trial evaluating stenoparib in patients wi
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP® companion diagnostic- Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026 TARPON SPRINGS, Fla., MAY 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provide
- SECSEC Form 10-Q filed by Allarity Therapeutics Inc.10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)
- INSIDERCEO Jensen Thomas was granted 200,000 shares, increasing direct ownership by 50% to 596,734 units (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- INSIDERDirector Hoeiland Jesper was granted 25,000 shares (SEC Form 4)4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hoeiland Jesper3 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
- SECAllarity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
- PRAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmTARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.Presentation Details: Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST Mr. Jensen will discus
ALLR FAQ
6 questionsWhat does Allarity Therapeutics Inc. do?
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials...Where does ALLR stock trade?
Allarity Therapeutics Inc. (ALLR) is listed on NASDAQ.What sector and industry is ALLR in?
Allarity Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ALLR?
Allarity Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ascendiant Capital Markets: Buy with a $900.00 price target on 2025-07-28. Recent price targets cluster around $900.00.What companies are similar to ALLR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ALLR side-by-side with any of them on Quantisnow.How can I track ALLR on Quantisnow?
Quantisnow aggregates Allarity Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALLR to receive live email and push alerts on every new disclosure.